LIPELLA PHARMACEUTICALS INC (LIPO) Fundamental Analysis & Valuation

NASDAQ:LIPO • US53630L2097

Current stock price

2.36 USD
-0.35 (-12.75%)
At close:
1.8001 USD
-0.56 (-23.72%)
After Hours:

This LIPO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. LIPO Profitability Analysis

1.1 Basic Checks

  • LIPO had negative earnings in the past year.
  • LIPO had a negative operating cash flow in the past year.
  • LIPO had negative earnings in each of the past 5 years.
  • In the past 5 years LIPO always reported negative operating cash flow.
LIPO Yearly Net Income VS EBIT VS OCF VS FCFLIPO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -1M -2M -3M -4M -5M

1.2 Ratios

  • LIPO has a Return On Assets of -105.66%. This is in the lower half of the industry: LIPO underperforms 77.78% of its industry peers.
  • LIPO's Return On Equity of -125.78% is in line compared to the rest of the industry. LIPO outperforms 40.86% of its industry peers.
Industry RankSector Rank
ROA -105.66%
ROE -125.78%
ROIC N/A
ROA(3y)-120.13%
ROA(5y)-91.9%
ROE(3y)-154.59%
ROE(5y)-121.63%
ROIC(3y)N/A
ROIC(5y)N/A
LIPO Yearly ROA, ROE, ROICLIPO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -100 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for LIPO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LIPO Yearly Profit, Operating, Gross MarginsLIPO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. LIPO Health Analysis

2.1 Basic Checks

  • LIPO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, LIPO has more shares outstanding
  • The number of shares outstanding for LIPO has been reduced compared to 5 years ago.
  • There is no outstanding debt for LIPO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LIPO Yearly Shares OutstandingLIPO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
LIPO Yearly Total Debt VS Total AssetsLIPO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

  • Based on the Altman-Z score of 0.93, we must say that LIPO is in the distress zone and has some risk of bankruptcy.
  • LIPO's Altman-Z score of 0.93 is fine compared to the rest of the industry. LIPO outperforms 65.59% of its industry peers.
  • LIPO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.93
ROIC/WACCN/A
WACC8.93%
LIPO Yearly LT Debt VS Equity VS FCFLIPO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 2M -2M 4M

2.3 Liquidity

  • LIPO has a Current Ratio of 6.21. This indicates that LIPO is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 6.21, LIPO is doing good in the industry, outperforming 62.01% of the companies in the same industry.
  • LIPO has a Quick Ratio of 6.21. This indicates that LIPO is financially healthy and has no problem in meeting its short term obligations.
  • LIPO's Quick ratio of 6.21 is fine compared to the rest of the industry. LIPO outperforms 62.54% of its industry peers.
Industry RankSector Rank
Current Ratio 6.21
Quick Ratio 6.21
LIPO Yearly Current Assets VS Current LiabilitesLIPO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. LIPO Growth Analysis

3.1 Past

  • LIPO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -56.74%.
  • LIPO shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.88%.
  • Measured over the past years, LIPO shows a decrease in Revenue. The Revenue has been decreasing by -5.04% on average per year.
EPS 1Y (TTM)-56.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.42%
Revenue 1Y (TTM)8.88%
Revenue growth 3Y27.4%
Revenue growth 5Y-5.04%
Sales Q2Q%-11.31%

3.2 Future

  • Based on estimates for the next years, LIPO will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.87% on average per year.
  • Based on estimates for the next years, LIPO will show a very negative growth in Revenue. The Revenue will decrease by -41.42% on average per year.
EPS Next Y33.76%
EPS Next 2Y-48.97%
EPS Next 3Y19.87%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
LIPO Yearly Revenue VS EstimatesLIPO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K
LIPO Yearly EPS VS EstimatesLIPO Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

0

4. LIPO Valuation Analysis

4.1 Price/Earnings Ratio

  • LIPO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LIPO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LIPO Price Earnings VS Forward Price EarningsLIPO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LIPO Per share dataLIPO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

  • A more expensive valuation may be justified as LIPO's earnings are expected to grow with 19.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.97%
EPS Next 3Y19.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LIPO Dividend Analysis

5.1 Amount

  • LIPO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

LIPO Fundamentals: All Metrics, Ratios and Statistics

LIPELLA PHARMACEUTICALS INC

NASDAQ:LIPO (6/18/2025, 8:03:30 PM)

After market: 1.8001 -0.56 (-23.72%)

2.36

-0.35 (-12.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)03-28
Earnings (Next)N/A
Inst Owners1.41%
Inst Owner Change0%
Ins Owners6.52%
Ins Owner Change0%
Market Cap10.55M
Revenue(TTM)519.90K
Net Income(TTM)-5.13M
Analysts82.86
Price Target10.2 (332.2%)
Short Float %0.06%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 20.29
P/FCF N/A
P/OCF N/A
P/B 2.59
P/tB 2.59
EV/EBITDA N/A
EPS(TTM)-4.1
EYN/A
EPS(NY)-17.77
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0.12
BVpS0.91
TBVpS0.91
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -105.66%
ROE -125.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.13%
ROA(5y)-91.9%
ROE(3y)-154.59%
ROE(5y)-121.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.21
Quick Ratio 6.21
Altman-Z 0.93
F-Score5
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-56.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.42%
EPS Next Y33.76%
EPS Next 2Y-48.97%
EPS Next 3Y19.87%
EPS Next 5YN/A
Revenue 1Y (TTM)8.88%
Revenue growth 3Y27.4%
Revenue growth 5Y-5.04%
Sales Q2Q%-11.31%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-6.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-24.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.41%
OCF growth 3YN/A
OCF growth 5YN/A

LIPELLA PHARMACEUTICALS INC / LIPO Fundamental Analysis FAQ

What is the fundamental rating for LIPO stock?

ChartMill assigns a fundamental rating of 2 / 10 to LIPO.


What is the valuation status of LIPELLA PHARMACEUTICALS INC (LIPO) stock?

ChartMill assigns a valuation rating of 0 / 10 to LIPELLA PHARMACEUTICALS INC (LIPO). This can be considered as Overvalued.


How profitable is LIPELLA PHARMACEUTICALS INC (LIPO) stock?

LIPELLA PHARMACEUTICALS INC (LIPO) has a profitability rating of 0 / 10.


Can you provide the financial health for LIPO stock?

The financial health rating of LIPELLA PHARMACEUTICALS INC (LIPO) is 7 / 10.